Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser, P. Cramer, F. Demirkan, R. Santucci Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, N. L. Bartlett, M. S. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, M. A. Pavlovsky, C. KarlssonM. Hallek, M. Mahler, M. Salman, S. Sun, C. Phelps, S. Balasubramanian, A. Howes, A. Chanan-Khan
Dive into the research topics of 'Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma'. Together they form a unique fingerprint.